Free breakfast, airport shuttle and parking about 10 miles from the October 17–21 show

GREENSBORO, N.C., Sept. 30, 2026 /PRNewswire/ -- SpringHill Suites by Marriott Greensboro Airport is ready to host attendees of High Point Market Fall 2026, which runs October 17–21 in High Point, North Carolina. The hotel sits about 10 miles from High Point Market and 7.2 miles from Piedmont Triad International Airport (PTI). The location makes it a good fit for design professionals, retailers and industry partners looking for a hotel near High Point Market.

The all-suite SpringHill Suites Greensboro Airport gives market-goers room to work, rest and recharge between long showroom days. Complimentary amenities include:

- A free buffet breakfast (6:30–9:00 a.m. weekdays and 7:00–9:30 a.m. weekends)

- A free airport shuttle to and from PTI, available Monday through Friday from 9 a.m. to 5 p.m. by request

- Free on-site parking

- Free Wi-Fi for Marriott Bonvoy members

- An indoor pool and a 24-hour fitness center

The hotel also has an on-site bar serving beer and light bites, plus meeting space for small showroom recaps and client meetings.

"After a full day at High Point Market, relax at Springhill Suites Greensboro Airport, where our welcoming team offers genuine Southern hospitality," said Judy Thomas, Director of Sales.

SpringHill Suites by Marriott Greensboro Airport is located at 505 Hickory Branch Road, Greensboro, NC 27409. It is also close to the Greensboro Coliseum and High Point University. To book a stay for High Point Market 2026, visit marriott.com/gsosa or call 336-884-4900.

ABOUT BRANDT HOSPITALITY GROUP

Brandt Hospitality Group is a hotel development and management company based in Fargo, North Dakota, that builds and operates award-winning hotels from coast to coast. In 2026, Marriott International recognized Brandt Hospitality Group with its Partnership Circle award. Learn more at brandthg.com.

SOURCE Brandt Hospitality Group

Share this article

In the news release, Reel Wheels Entertainment™ Unveils Hundreds of Film and Television Icons, Backed by Award-Winning Hollywood Talent, issued 30-Sep-2026 by Reel Wheels Entertainment LLC. over PR Newswire, we are advised by the company that the original version did not include public-facing contact details as incorrectly formatted by PR Newswire.

Reel Wheels Entertainment™ Unveils Hundreds of Film and Television Icons, Backed by Award-Winning Hollywood Talent

The extraordinary private collection spans vehicles, aircraft, props, wardrobe and memorabilia, forming the foundation of a new global experiential entertainment platform.

LOS ANGELES, Sept. 30, 2026 /PRNewswire/ -- Maybe it was the Lamborghini Countach poster on your bedroom wall. Maybe it was Jake Ryan's Porsche 944 in Sixteen Candles. Maybe it was the Thunderbird from Thelma & Louise.

Somewhere along the way, a car stopped being transportation and became part of a memory.

For the past three years, Reel Wheels Entertainment™ ("Reel Wheels") has been assembling those memories in physical form.

Now, the company is stepping into the public spotlight with a private collection spanning hundreds of vehicles, aircraft, props, wardrobe, memorabilia and entertainment assets connected to some of the most recognizable movies, television shows and moments in popular culture.

At a time when almost anything can be generated, streamed or digitally recreated, Reel Wheels is building around something increasingly powerful: real community formed around physical objects people can see up close and experience together.

But Reel Wheels is not being developed as a traditional museum, and the cars themselves are only the beginning.

"The cars are the gateway," said Aaron Phillips, CEO of Reel Wheels. "They open the door into an entire world of film and television. The characters, scenes, props, music and memories people already carry with them."

Phillips describes the vision as a cultural time tunnel, reconnecting audiences with what they loved growing up, surrounding them with what they love today, and creating anticipation for what comes next.

FROM COLLECTION TO EXPERIENCE

The collection includes original screen-used pieces, production-related artifacts and recreations, with provenance identified individually.

Among its holdings is the original screen-used cockpit from Airplane! Co-writer and co-director Jerry Zucker recently sat down with Reel Wheels for an interview about the film, the cockpit and why physical pieces of filmmaking still matter decades later. Reel Wheels plans to release that conversation soon.

"These objects also carry memories that belong to the audience as much as to us. People tell me they watched Airplane! with their dad, or on a first date, or at a sleepover where they laughed until they couldn't breathe. Seeing something real from the film brings that moment back. It connects people to a time in their own lives, not just to the movie," Zucker said.

Other highlights include an aircraft used in M*A*S*H, a screen-used mid-engine Dodge Charger from F9: The Fast Saga, a production aircraft fuselage associated with Sully, an original production stunt proton pack from Ghostbusters, The Cannonball Run ambulance, and vehicles, props and wardrobe connected to Men in Black and other celebrated film and television properties.

The assets currently visible publicly represent only a portion of Reel Wheels' holdings. Additional vehicles, aircraft and significant entertainment memorabilia continue to be documented and introduced.

A WORLD-CLASS TEAM OF INDUSTRY VETERANS

Reel Wheels has assembled a world-class design and production team capable of helping brands, studios, resorts, hospitality groups and destination developers integrate Reel Wheels assets into their own creative vision, from a single high-impact activation to a fully developed immersive environment.

Rick Carter, advisor to Reel Wheels, is a two-time Academy Award-winning production designer whose credits include Avatar, Lincoln, Jurassic Park, Forrest Gump and The Fabelmans.

"What could be more real than Reel Wheels?" Carter said. "These are the cars we all dreamed of driving and owning, the cars that made us want to be those characters and ignited our sense of speed, adventure and imagination in the 'reel worlds' of classic movies."

Doug Meerdink, Chief Creative Officer of Reel Wheels, has spent more than two decades working in feature-film art direction and production design.

"Reel Wheels gives us the opportunity to extend cinematic storytelling beyond the screen," Meerdink said. "By placing extraordinary physical assets at the center of immersive environments, we can transport audiences directly into the stories they love."

Veteran picture-car specialist Dennis McCarthy, founder of Vehicle Effects and advisor to Reel Wheels, brings decades of experience across more than 100 motion pictures, including extensive work throughout the Fast & Furious franchise, Batman v Superman: Dawn of Justice and Avengers: Endgame.

"Cars in movies and television are more than transportation, they're characters," McCarthy said. "The right car can tell you who someone is before they ever say a word."

BUILT AROUND A PARTNER'S VISION

"We don't expect a partner to build their vision around our collection," Phillips said. "Our job is to understand their vision and use our assets, designers and production capabilities to help make it extraordinary."

Potential applications range from brand activations and resort programming to touring entertainment, studio collaborations and permanent destination-scale attractions.

Reel Wheels is also exploring opportunities internationally, including in Qatar, Saudi Arabia and the United Arab Emirates, as investment in tourism, hospitality and location-based entertainment creates opportunities for ambitious physical experiences at scale.

"A recognizable car may be what gets someone through the door," Phillips said. "But the destination is the world it came from."

AN INVITATION TO CREATE

Reel Wheels is inviting filmmakers, production designers, technologists, global brands, hospitality leaders, studios, destination developers and storytellers to imagine what can be built around the collection.

"After three years of collecting, preserving, building and imagining what Reel Wheels could become, we're ready to open the door," Phillips said.

The cars are the gateway. The stories are the destination.

ABOUT REEL WHEELS

Reel Wheels is an experiential entertainment company built around a private collection spanning hundreds of vehicles, aircraft, props, wardrobe, memorabilia and entertainment assets connected to film, television and popular culture. The company is backed by a world-class team of industry veterans spanning production design, art direction, picture cars and experiential entertainment, bringing decades of experience from major motion pictures and global entertainment projects.

The collection includes assets with differing provenance, including original screen-used pieces, production-related assets and recreations. Reel Wheels identifies provenance individually and does not represent every asset as an original screen-used piece.

The publicly displayed collection represents only a portion of Reel Wheels' holdings, with additional vehicles, aircraft and entertainment memorabilia continuing to be documented and introduced.

For media inquiries, partnership opportunities, collection-related questions, or to learn more about Reel Wheels Entertainment™, please contact Aaron Phillips directly at [email protected] or by phone 310 879 5289

Share this article

Sports teams, music, fashion, local artisans and family activities celebrate a new national home for youth gatherings in Indiana

SPICELAND, Ind., Sept. 30, 2026 /PRNewswire/ -- Spiceland National Youth Campus officially opened with a vibrant culture and sports festival bringing together young people, families and guests from across the country.

Sports teams traveled from around the United States to compete and connect, while the festival featured live music, a fashion show, artisanal vendors and family-friendly activities. The celebration welcomed people from all walks of life for a weekend centered on community, culture and connection.

Spiceland National Youth Campus Opened by Family Federation With Culture & Sports Festival

Spiceland National Youth Campus Opened by Family Federation With Culture & Sports Festival

Spiceland National Youth Campus Opened by Family Federation With Culture & Sports Festival

Located in Spiceland, Indiana, the private retreat campus was created for youth camps, educational programs, leadership experiences and other meaningful gatherings. Facilities include dorm accommodations, a main lodge with meeting and breakout spaces, a commercial kitchen and an outdoor pavilion accommodating up to 200 people.

The opening marks an exciting new chapter: a dedicated national home where young people from across America can gather, build friendships, develop leadership and create experiences that can shape a lifetime.

Share this article

STANCRAFT-LED INVESTOR GROUP ANNOUNCES PLAN TO REIMAGINE TEMPLIN'S ON THE RIVER AND MARINA 33

Repositioning effort will honor Templin's 40-year legacy while expanding Marina 33's live music, dining, boating and slip ownership offerings for the Post Falls community

POST FALLS, Idaho, Sept. 30, 2026 /PRNewswire/ -- StanCraft, a Hayden, Idaho-based family of companies, together with an investor group, today announced the next step in its long-term effort to reposition Templin's on the River ("Templin's"), the landmark hotel and resort that has anchored Post Falls' waterfront for four decades. The hotel will close on October 23rd, 2026, while the ownership group evaluates options to reinvigorate the property, which may include remodeling or redevelopment. Throughout this process, Marina 33 continues to grow as one of the region's most vibrant gathering places on the water.

Since acquiring the waterfront hotel, bar and marina in 2024, StanCraft and its partners have invested steadily in the property by refreshing amenities, introducing new food and beverage offerings, enhancing the grounds, and expanding Marina 33 and its offerings for boaters and the broader community. Now, following a comprehensive assessment of the property's potential, the ownership group has determined that the best path forward is to close the hotel while it evaluates how to reposition the property, with the goal of elevating the guest experience while preserving what has always made Templin's and Marina 33 special: their deep roots on the Spokane River.

"Templin's has been a staple of Post Falls for generations," said StanCraft. "As proud stewards of this iconic property, we believe taking the time to thoughtfully evaluate its future is the right way to ensure Templin's continues to create memorable experiences for generations to come. We are committed to honoring Templin's legacy and the natural beauty of the river while building an extraordinary destination that brings families, neighbors and visitors together, strengthening the Post Falls community we call home."

A New Chapter on the Water for Marina 33

While the hotel is closed and next steps are evaluated, Marina 33 remains open, fully operational, and central to StanCraft's vision for the waterfront. The marina has become a true gathering place — where neighbors and visitors come together on the river — and StanCraft is continuing to invest in the experiences that make Marina 33 special, including live music, artisan food trucks, and family-friendly events that bring the community together throughout the season. 

Boaters and visitors can also look forward to expanded amenities designed to make the most of life on the Spokane River, including:

- Boat and water sport rentals for a day on the river

- A new fixed pier boardwalk along the water's edge

- Public side-tie and day parking for boats, making it easier than ever to spend a day on the water

- Slip rentals and slip ownership opportunities, for those who want to put down roots on the water for years to come

"Marina 33 is where this community comes together," said StanCraft. "From live music on the docks to families spending the day on the water, this is the kind of gathering place the Spokane River deserves — and we're just getting started."

Additional details on the future of the hotel property will be shared as plans progress. Marina 33 remains open and fully operational for marina tenants and visitors throughout the transformation.

About StanCraft 

StanCraft is a family-owned group of companies founded in 1933 with the making of custom mahogany wooden boats. The company has grown to include StanCraft Marine Construction, StanCraft Construction Group and the StanCraft Jet Center, employing over 250 people in North Idaho. StanCraft is known for its craftsmanship, quality and attention to detail across all of its companies. 

SOURCE Stancraft

Share this article

STAMFORD, Conn., Sept. 30, 2026 /PRNewswire/ -- Aircastle Limited ("Aircastle") announced today that it plans to release its second quarter financial results for the period ended August 31, 2026, before the market opens on October 14, 2026.

In connection with this press release, management will host a conference call on Wednesday, October 14, 2026, at 9:00 A.M. Eastern Time. All interested parties are welcome to participate in the live call. The conference call can be accessed by dialing +1 (800) 836-8184 (from within the U.S. and Canada) or +1 (646) 357-8785 (outside the U.S. and Canada) ten minutes prior to the scheduled start. Please reference our company name, "Aircastle" when prompted by the operator.

A simultaneous webcast of the conference call will be available to the public on a listen-only basis at www.aircastle.com. Please allow extra time prior to the call to visit the site and download the necessary software required to listen to the internet broadcast.

For those who are not available to listen to the live call, a replay of the webcast will be available on Aircastle's website shortly after the conclusion of the live call.

About Aircastle Limited

Aircastle Limited acquires, leases, and sells commercial jet aircraft to airlines worldwide. As of May 31, 2026, Aircastle owned and managed 279 aircraft leased to 72 customers located in 43 countries.

Contact:

Aircastle (Ireland) DAC (US)                                              

Jim Connelly, SVPESG & Corporate Communications

Tel: +1 (203) 504-1871

[email protected] 

SOURCE Aircastle Ireland DAC

Share this article

Saronic Breaks Ground on Port Alpha, a New Model for American Shipbuilding

Vice President JD Vance and Governor Greg Abbott join Saronic in Brownsville, Texas, to break ground on Port Alpha, the next milestone in the company's plan to rebuild American shipbuilding capacity at speed and scale

BROWNSVILLE, Texas, Sept. 30, 2026 /PRNewswire/ -- Saronic today announced the groundbreaking of Port Alpha, a next-generation American shipyard built to restore the nation's maritime industrial capacity. Situated on 835 acres at the Port of Brownsville with the option to expand to nearly 4,400 acres, Port Alpha represents a private capital investment of more than $3 billion. The shipyard, which will be capable of building both autonomous and manned ships, is expected to generate up to 10,000 direct jobs and create an estimated $264.5 billion in economic impact for the State of Texas, making it one of the largest economic development projects in modern Texas history.

Restoring American shipbuilding is a national priority. Port Alpha is coming online to provide the capacity, capability, and speed the moment demands, echoing the Administration's Executive Order "Restoring America's Maritime Dominance," the Maritime Action Plan, and the U.S. Navy's shipbuilding plans to support a hybrid fleet, each calling for the same thing: a stronger, U.S.-built commercial and defense fleet ready to take on the challenges of today and tomorrow.

That convergence is what is bringing federal, state, and local leaders to the Brownsville waterfront for the historic groundbreaking event. Saronic was honored to host Vice President JD Vance and Governor Greg Abbott along with federal, state, and local officials, critical partners, members of the Brownsville community, and Saronic leadership at the site, where Vance and Abbott delivered remarks on what Port Alpha means for national security, economic prosperity, and freedom of the seas.

"American shipbuilding needs to be rebuilt for what comes next," said Dino Mavrookas, Co-Founder and CEO of Saronic, speaking at the ceremony. "Port Alpha is where that starts. We're honored to have Vice President Vance and members of Congress here in Brownsville as we break ground here today. Port Alpha is designed from the ground up to produce both autonomous and manned vessels at scale, with modularity and throughput shaping the shipyard's architecture. This is one of the defining engineering challenges of our time, and we are building the team, partnerships, and capital base to meet it."

"Texas is the new leader in American shipbuilding," said Governor Abbott. "Port Alpha will create 10,000 jobs and put hundreds of millions of dollars in annual paychecks into the hands of Texans. These ships will be built in Brownsville by American workers for the defense of the United States."

An Innovative Approach to Building Ships

The innovation at Port Alpha is the shipyard itself. Saronic is building a clean-sheet, software-defined facility designed from the ground up to deliver autonomous, autonomy-capable, and manned ships at speed and scale. At opening, Port Alpha will introduce an initial 150,000 gross tons of annual shipbuilding capacity — more than doubling current U.S. commercial shipbuilding capacity — with the potential to scale to over 2 million gross tons. Port Alpha will initially be capable of producing vessels up to 850 feet, while future site expansion could support production of vessels over 1,200 feet, ultimately making it the largest shipyard in America.

That capacity expands what the nation can build for defense and commercial customers alike, with the goal of supplementing existing U.S. shipbuilders and supporting U.S. allies and partners who face the same backlog and capacity squeeze.

Building for the Future Starts Today

Saronic is taking a phased approach to building Port Alpha, beginning operations with initial production capacity that allows the company to employ its manufacturing approach and establish workforce pipelines. At initial operations, Port Alpha will encompass 1.2 million square feet of enclosed production space within a 2.5-million-square-foot production activity area, spread across 8 to 10 dedicated production buildings and served by more than 2,500 feet of deepwater quay. Two to four build positions will handle final ship erection, supported by 75,000 tonnes — 150 million pounds — of annual steel processing capacity. Saronic has selected JE Dunn | Alberici Joint Venture to construct this initial phase, bringing decades of experience on large commercial projects and industrial builds.

This first phase will focus on building autonomous, autonomy-capable, and manned ships, including Landing Craft Utility (LCU) vessels for the U.S. Navy. Saronic was recently awarded a contract to build these core Navy logistics vessels, taking on an immediate and urgent need for the Fleet today while continuing to ramp to meet the needs of an autonomous maritime future.

For the nation, this phase begins to immediately close the capacity gap, allowing Saronic to build its workforce and supply chain and validate its manufacturing approach.

A Long-Term Commitment

Today's groundbreaking marks the beginning of a long-term commitment to Brownsville and the American shipbuilding workforce. Over the next decade, Saronic expects Port Alpha to create up to 10,000 high-quality direct jobs, from skilled trades such as welding and machining to advanced roles in robotics, software engineering, and naval architecture. Saronic is working with the State of Texas, Cameron County, and regional educational institutions on engineering pipelines, technical training, and apprenticeship pathways designed to put those careers within reach for the community and state of Texas, and to help address a national shortfall of roughly 250,000 skilled shipbuilding workers over the next decade.

Saronic is building Port Alpha with discipline and a commitment to revitalize a critical pillar of U.S. industry. It is also one part of a broader national reindustrialization effort, and one that will require government and industry to play their part together. Strategic investment, strong partnerships, and clear regulatory pathways can accelerate production, expand industrial capacity, and help restore America's position as the world's leading maritime power.

"This is bigger than one shipyard," Mavrookas said. "What stands on this ground in five years — the supplier base, the workforce, the ships themselves — is what will determine whether America leads at sea for the next century. We're ready to be a critical part of that narrative."

Contact: [email protected]

SOURCE Saronic

Share this article

COLUMBUS, Ga., Sept. 30, 2026 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) announced today that it will release third quarter 2026 financial results after the market closes on Wednesday, November 4, 2026. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be available, along with a financial update video from Senior Executive Vice President and Chief Financial Officer Max K. Brodén, on the company's Investor Relations website, investors.aflac.com.

Aflac Incorporated will also webcast a conference call scheduled for 8:00 a.m. (ET) on Thursday, November 5, 2026. During the webcast, Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos, along with Brodén, will discuss the company's quarterly results. President of Aflac Incorporated and Aflac U.S. Virgil R. Miller will join them to answer questions during the webcast with other members of executive management from the U.S. and Japan. To listen to the conference call, please register at investors.aflac.com five to seven minutes prior to the scheduled start time.

ABOUT AFLAC INCORPORATED

Aflac Incorporated (NYSE: AFL), a Fortune 500 company, has helped provide financial protection and peace of mind for more than seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan. In the U.S., Aflac is the No. 1 provider of supplemental health insurance products.1 In Japan, Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force.2 The company takes pride in being there for its policyholders when they need us most, as well as being included in the World's Most Ethical Companies by Ethisphere for 20 consecutive years (2026) and Fortune's World's Most Admired Companies for 25 years (2026). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021. To find out how to get help with expenses health insurance doesn't cover, get to know us at aflac.com or aflac.com/español. Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at investors.aflac.com under "Sustainability."

1 LIMRA 2025 U.S. Supplemental Health Insurance Total Market Report

2 As of March 31, 2025, Aflac estimates based on company data.

Aflac Incorporated periodically provides information for investors on its corporate website, investors.aflac.com, including information regarding its commitment to corporate social responsibility and sustainability, press releases, financial information, SEC filings, corporate governance materials, annual meeting information, and other information that may be important to investors.

Analyst and investor contact – David A. Young, 706.596.3264 or 800.235.2667, or [email protected]

Media contact – Ines Gutzmer, 762.207.7601 or [email protected]

SOURCE Aflac Incorporated

Share this article

Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion

TEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported operational highlights and financial results for the six months ended June 30, 2026.

Commercial portfolio update:

- $12 million upfront payment to Ferring for the acquisition of commercialization rights to Rebyota® and Clenpiq®, fully funded by the $18 million received upfront for the Talicia® divestment

- Transactions strengthen liquidity, provide potential growth and expansion opportunities and enable addition of complementary revenue-generating products

- RedHill's lean commercial infrastructure supports delivery of significant synergies with capacity for further portfolio extension

Dror Ben-Asher, RedHill's Chief Executive Officer, said: "We have executed on two major transactions that unlock significant value and fuel our capacity for growth. The acquisition of commercial rights to Rebyota® and Clenpiq®, funded by sale of Talicia, improves our liquidity position and provides us with control to drive increased revenues, identify additional complementary revenue-generating products and support ongoing development of our assets. We are now focused on the rapid and smooth transition of Rebyota® and Clenpiq® into RedHill, utilizing our lean and efficient commercial team, which is already well positioned and deeply embedded in the U.S. GI market."

Mr. Ben-Ashercontinued: "Looking forward to the second half of 2026 and beyond, we also aim to progress our R&D development projects, which provide compelling opportunities in areas of significant unmet need, including multiple oncology indications, Crohn's disease and other GI-associated conditions and Ebola virus disease (EBOV). In oncology, opaganib has been granted the U.S. Food and Drug Administration's rare pediatric disease designation for neuroblastoma, with potential to receive an accompanying Priority Review Voucher. Furthermore, new preclinical data supportive of opaganib add-on therapy in neuroblastoma and triple negative breast cancer was presented at AACR, while recruitment continues into the Bayer-supported Phase 2 study of opaganib and darolutamide in advanced castrate resistant prostate cancer. Progress has also been made on key aspects of our Phase 2-ready Crohn's program with RHB-204, potentially the first ever in a wholly MAP-positive population, with in vitro assay data demonstrating RHB-204's comparable MAP killing to RHB-104. Meanwhile, RHB-102 continues its late-stage development for oncology support and GI indications including GLP-1/GIP-associated GI intolerance."

Commercial focus:

Following the divestment of RedHill's 70% stake in Talicia for $18 million in upfront cash, plus up to $35 million in potential worldwide net sales milestone payments, the Company has acquired for an upfront cash payment of $12 million, plus future milestones and tiered royalties, the exclusive global and U.S. commercialization rights to Rebyota® and Clenpiq®, respectively, two synergistic, revenue-generating, FDA-approved GI drugs that together generated approximately $37.5 million in 2025 net sales under Ferring.

With a growing medical need, the potential for expanded indications and territories, and an experienced and efficient commercial infrastructure that is highly established within the GI market, these two new assets provide RedHill with a stronger commercial engine for revenue growth, in both the U.S. and other new territories, with potential for further added value through acquisition of additional complementary revenue-generating products.

Rebyota:

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT) for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and established customer base.

C. diff(CDI) infection is a distressing and life-threatening condition, being the most common cause of healthcare-associated (HA) diarrhea in developed countries1. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI2, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences3, indicating the need for use of prevention strategies.

Rebyota's one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI4. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence5.

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations, with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Clenpiq:

Clenpiq is a ready-to-drink, low-volume bowel preparation on the U.S. market. In 2025, it delivered $20.6 million in net sales, with minimal promotion under Ferring. Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually6. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy.

Bowel preparation quality drives outcomes and cost, but it is not a pleasant process and is often poorly performed – driving the need for repeated procedures. As such the benefits of a simplified, ready-to-drink, low-volume bowel preparation are evident. Clenpiq has broad commercial and government payer coverage making its benefits readily accessible to patients: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23 million lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12 million (21%) lives with preferred position5.

Focused and advanced R&D pipeline – first half of 2026 highlights:

- Opaganib granted U.S. Food and Drug Administration (FDA) rare pediatric disease designation for neuroblastoma, the most prevalent cancer in infants, providing potential for an accompanying Priority Review Voucher (PRV)

- New preclinical data showed positive effects of opaganib as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC). Two sets of data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting indicate that:

- Opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin (OXDOX) chemotherapy combination in high-risk NB by directly destabilizing n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, through increased ceremide production enhancing programmed cell death (apoptosis) in cancer cells7

- Pre-treatment with opaganib, followed by low-dose diABZI treatment, potentiated the downstream STING-mediated effects and may augment anti-tumor immunity in TNBC, which has the poorest prognosis of the breast cancer subtypes8

- Opaganib Ebola (Bundibugyo, BDBV) development next steps and potential partnership discussions ongoing with African Medicines Agency, Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee

- In Crohn's disease, new RHB-204in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-1049. RHB-204 achieved these results with lower doses of key active ingredients enhancing potential for reduced toxicity and side effects, supporting an innovative FDA-aligned Phase 2-ready study design allowing for a smaller sample size, lower study costs and faster time to completion

Financial results for the six months ended June 30, 2026 (Unaudited) 10

Following the transfer of the Talicia commercial operations to Talicia Holding Inc. ("THI") in October 2025, Talicia's operations are presented as "discontinued operations" in RedHill's financial statements. The comparison below is therefore presented on a continuing operations basis, with first half of 2025 comparative figures re-presented on the same basis. RedHill's ongoing economic participation in the Talicia franchise during the period is reflected separately as its share of loss of the joint venture. RedHill sold its entire 70% interest in THI to Apotex in August 2026.

Net Revenues: No revenues were recognized in the first half of 2026, compared to $0.3 million in the first half of 2025, which was generated from the Hyloris license agreement for RHB-102 (Bekinda®).

Research and Development Expenses for the first half of 2026 were $1.0 million, unchanged from the first half of 2025. During the first half of 2026, the Company continued preclinical work related to RHB-204 and opaganib in Ebola.

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceutical executive with more than three decades of commercial leadership experience and a proven track record of shaping the profile of innovative therapies resulting in highly successful launches of respiratory, oncology and immunology therapies.

"We are delighted to welcome Jim back to Halozyme's Board of Directors," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Jim brings exceptional industry knowledge, commercial expertise, strategic insight, and governance experience. His extensive background leading the launches and growth of multiple blockbuster therapies will be invaluable as Halozyme continues to expand the number of products using our subcutaneous (SC) delivery technologies, ENHANZE, and our two hyperconcentration technologies, Hypercon and Aerocon."

Mr. Daly previously served on Halozyme's Board of Directors and has held senior commercial leadership roles across leading global biopharmaceutical companies.

He served as Executive Vice President and Chief Commercial Officer of Incyte Corporation from 2012 to 2015. Prior to Incyte, he spent a decade at Amgen, where he held senior commercial leadership positions, including his most recent role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, Mr. Daly spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, where he held positions of increasing responsibility, including Senior Vice President and General Manager of the U.S. respiratory business.

"I am pleased to rejoin Halozyme's Board at such an exciting time in the company's evolution," said Mr. Daly. "Halozyme has created an impressive portfolio of SC delivery technologies, with ENHANZE the clear gold standard in terms of large volume SC delivery, and Hypercon and Aerocon leading the way to enabling more at home delivery of biologic medicines. I am excited to work with the management team and the Board to continue to transform the patient treatment experience and potentially outcomes."

Mr. Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals and Cytokinetics. He previously served on the boards of argenx, Bellicum Pharmaceuticals and Chimerix.

He holds a Bachelor of Science in Pharmacy and an M.B.A. from the University at Buffalo, State University of New York.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. Aerocon's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Aerocon™ complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Safe Harbor Statement

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Contact:

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

[email protected] 

SOURCE Halozyme Therapeutics, Inc.

Share this article

CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS), a leading marketplace for automotive sales, today announced that Trent Ziegler has been appointed the company's next Chief Financial Officer-Designate, effective October 19, 2026. He will formally assume the role of CFO, succeeding Sonia Jain, on November 6, 2026. In order to ensure an orderly transition, Jain will serve as an Executive Advisor to the company through March 31, 2027.

Ziegler joins Cars.com from FairSquare, a fintech holding company, where he served as CFO. Before that, he spent more than a decade at LendingTree, an online lending marketplace, including three years as CFO and seven years leading Investor Relations and Treasury. During that time, he helped the company deliver meaningful improvements in profitability, optimized cost structure, and successfully executed complex financing initiatives and growth-oriented acquisitions. Ziegler has extensive experience in financial planning and analysis, with a strong track record of translating financial insights into disciplined decision-making and business performance. He began his career at Ally Financial Inc.

"We are excited to welcome Trent as Cars.com's next CFO," said Tobi Hartmann, Chief Executive Officer of Cars.com. "Trent brings deep marketplace experience and a strong combination of strategic perspective, financial discipline and operational execution. He will help us strengthen performance and create value for our shoppers, customers and shareholders."

"Cars.com has strong fundamentals and real opportunity ahead," said Ziegler. "I'm looking forward to working with the team to further scale the business, drive disciplined capital allocation, and deliver shareholder value."

"We want to thank Sonia for her partnership and contributions to Cars.com," Hartmann continued. "She has helped guide the company's post-spin off evolution by advancing financial infrastructure and systems, implementing value-based pricing, and strengthening the balance sheet. We are well positioned to build on that progress, and we wish her well."

About Cars.com

Cars.com (NYSE: CARS) is a leading marketplace for automotive sales. For over 25 years, we've combined the most reviews in the industry, straight answers, and tools that cut through the noise to help shoppers make confident car decisions. Our scaled marketplace paired with interconnected technology, data, and media gives dealers and OEMs everything they need to sell more cars. Learn more at Cars.com.

SOURCE Cars.com Inc.

Share this article